NCT07626775

Brief Summary

This was a prospective, observational cross-sectional study conducted at a tertiary care private hospital in India. The study was designed to comprehensively evaluate the prevalence, management strategies, and clinical outcomes of in-hospital hyperglycemia among adult inpatients. The study also explored the associations of metabolic biomarkers-fetuin-A and fibroblast growth factor-21 (FGF-21) as well as sarcopenic obesity and nutritional factors with clinical outcomes, including length of hospital stay (LOS), complications, and mortality. Institutional Ethics Committee approval was obtained prior to study initiation, and written informed consent was secured from all participants

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
362

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jan 2023

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2023

Completed
3.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2026

Completed
28 days until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2026

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

May 14, 2026

Completed
21 days until next milestone

First Posted

Study publicly available on registry

June 4, 2026

Completed
Last Updated

June 4, 2026

Status Verified

May 1, 2026

Enrollment Period

3.1 years

First QC Date

May 14, 2026

Last Update Submit

May 29, 2026

Conditions

Diabete Type 2Diabete MellitusHyperglycaemia (Diabetic)

Outcome Measures

Primary Outcomes (2)

  • To determine the prevalence of hyperglycemia

    To determine the prevalence of hyperglycemia and pre-existing or newly diagnosed type 2 diabetes mellitus (T2DM) among hospitalized patients

    10 Days

  • Assess clinical outcomes associated with hyperglycemia

    To assess clinical outcomes associated with hyperglycemia, including in-hospital complications, mortality, need for critical care support, and length of hospital stay (LOS)

    10 Days

Secondary Outcomes (6)

  • Prevalence of sarcopenic obesity

    10 Days

  • Analyze serum biomarker level fetuin-A

    10 Days

  • Analyze serum biomarker level FGF-21

    10 Days

  • Analyze serum biomarker level FGF-21

    10 Days

  • Analyze serum biomarker level fetuin-A

    10 Days

  • +1 more secondary outcomes

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Newly diagnosed type 2 diabetes mellitus (T2DM) or those presenting with hyperglycemia

You may qualify if:

  • Adult patients aged ≥18 years.
  • Patients with known or newly diagnosed type 2 diabetes mellitus (T2DM) or those presenting with hyperglycemia (random blood glucose ≥140 mg/dL) during hospitalization.
  • Both medical and surgical inpatients admitted for ≥24 hours

You may not qualify if:

  • Pregnant or lactating women.
  • Patients with type 1 diabetes mellitus or other specific types of diabetes (e.g., pancreatogenic, drug-induced).
  • Patients with chronic liver disease unrelated to diabetes or hepatic dysfunction secondary to viral hepatitis, autoimmune hepatitis, or alcohol abuse.
  • Critically ill patients requiring palliative care or those with advanced malignancy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Division Of Endocrinology & Diabetes

Gurgaon, Haryana, 122001, India

Location

Related Publications (2)

  • Bin Rakhis SA Sr, AlDuwayhis NM, Aleid N, AlBarrak AN, Aloraini AA. Glycemic Control for Type 2 Diabetes Mellitus Patients: A Systematic Review. Cureus. 2022 Jun 21;14(6):e26180. doi: 10.7759/cureus.26180. eCollection 2022 Jun.

    PMID: 35891859BACKGROUND

  • Wangnoo SK, Baruah MP, Lodha S, Sanyal D, Goyal R, Sooragonda BG, Chandrasekaran S, Vijay Kumar G. In-Hospital Management of Hyperglycemia: The Role of Insulin Degludec. Diabetes Ther. 2025 Apr;16(4):547-568. doi: 10.1007/s13300-025-01707-w. Epub 2025 Feb 27.

    PMID: 40014293BACKGROUND

Related Links

MeSH Terms

Conditions

Diabetes MellitusDiabetes Mellitus, Type 2Hyperglycemia

Condition Hierarchy (Ancestors)

Glucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System Diseases

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
7 Days
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Senior Endocrinology Researcher

Study Record Dates

First Submitted

May 14, 2026

First Posted

June 4, 2026

Study Start

January 1, 2023

Primary Completion

February 1, 2026

Study Completion

March 1, 2026

Last Updated

June 4, 2026

Record last verified: 2026-05

Locations

IN(1)